Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): May 2016

Volume: 17

Issue: 5

Affiliations

[1 ] Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: kpark@skku.edu.

[2 ] National Cancer Centre, Singapore, Singapore.

[3 ] Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia.

[4 ] State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.

[5 ] Chris O'Brien Lifehouse, Camperdown, NSW, Australia.

[6 ] Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong Sha Tin, Hong Kong.

[7 ] McGill University, Montreal, QC, Canada.

[8 ] National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.

[9 ] Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea.

[10 ] Shanghai Chest Hospital, Shanghai, China.

[11 ] Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

[12 ] Asan Medical Center, Seoul, South Korea.

[13 ] BC CancerAgency, Vancouver, BC, Canada.

[14 ] Seoul National University Hospital, Seoul, South Korea.

[15 ] Centre François Baclesse, Oncology, Caen, France.

[16 ] Karolinska University Hospital, Solna, Stockholm, Sweden.

[17 ] The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.

[18 ] Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.

[19 ] Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.

[20 ] Boehringer Ingelheim GmbH, Ingelheim, Germany.

[21 ] Hospital Universitario Doce de Octubre and CNIO, Madrid Spain.

Article

Publisher Item ID: S1470-2045(16)30033-X

DOI: 10.1016/S1470-2045(16)30033-X

PubMed ID: 27083334

SO-VID: 0ab58272-94ad-40b7-9da4-d71ed26b069c

History

Data availability:

Comments

Comment on this article

scite_

Cited by 490

See all cited by